Physician profile
Mohammad Katout
NPI 1033375464
$2,916.92
in general payments reported to CMS, 2019-2025
23 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.38 · 2020: $293 · 2021: $584 · 2022: $411 · 2023: $562 · 2024: $534 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Education: $312 · Consulting Fee: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.64 |
| Education | $311.98 |
| Consulting Fee | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $527.87 | 2020-2023 | Rayaldee |
| Astrazeneca Pharmaceuticals Lp | $445.83 | 2020-2023 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $312.94 | 2019-2022 | |
| Travere Therapeutics, INC. | $256.75 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.00 | 2021-2025 | |
| Amgen INC. | $174.05 | 2020-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $173.12 | 2025 | |
| Ardelyx, INC. | $151.22 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Fresenius USA Marketing, INC. | $118.22 | 2021-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $97.85 | 2022-2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $71.57 | 2022-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $66.73 | 2022-2025 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $60.14 | 2021-2023 | Oxlumo |
| Renalytix Ai, INC. | $59.56 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Horizon Therapeutics Plc | $46.00 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $24.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.76 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $18.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.35 | 2022 | |
| Lilly USA, LLC | $15.09 | 2024 | Jardiance |
| Scpharmaceuticals INC. | $14.40 | 2025 | |
| Pharmacosmos Therapeutics INC. | $14.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Katout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.